索磷布韦维帕他韦治疗基因2a型肝炎的疗效分析  

Efficacy Analysis of Sofosbuvir and Velpatasvir in the Treatment of Genotype 2a Hepatitis

作　　者：陈晖蓉 李晓晴 CHEN Huirong;LI Xiaoqing(Department of Infection,Zhangye People's Hospital Affiliated to Hexi College,Zhangye,Gansu Province,734000 China)

机构地区：[1]河西学院附属张掖人民医院感染科,甘肃张掖734000

出　　处：《中外医疗》2024年第16期71-74,78,共5页China & Foreign Medical Treatment

摘　　要：目的 探讨索磷布韦维帕他韦治疗基因2a型慢性丙型肝炎(Chronic Hepatitis C, CHC)合并2型糖尿病(Type 2 Diabetes, T2DM)患者的临床疗效。方法 方便选取2020年1月—2022年12月河西学院附属张掖人民医院收治的162例基因2a型CHC合并T2DM患者为研究对象,以随机数表法分为对照组与观察组,各81例。对照组给予利巴韦林+干扰素治疗,观察组在对照组基础上增加索磷布韦维帕他韦治疗。比较两组患者临床疗效、病毒应答率、肝功能指标、炎症因子、治疗安全性。结果 观察组治疗总有效率为92.59%,高于对照组的79.01%,差异有统计学意义(χ^(2)=6.131,P<0.05)。观察组患者的早期病毒学应答率、治疗结束时病毒学应答率、停药后24周病毒应答率和停药后48周病毒应答率均高于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组肝功能指标均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组炎症因子水平均低于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生对比,差异无统计学意义(P>0.05)。结论 索磷布韦维帕他韦治疗基因2a型CHC合并T2DM患者效果显著,可提高患者病毒应答率,改善肝功能指标,抑制炎症因子水平,安全性良好。Objective To explore the clinical efficacy of sofosbuvir and velpatasvir in the treatment of patients with genotype 2a chronic hepatitis C(CHC)combined with type 2 diabetes mellitus(T2DM).Methods 162 patients with genotype 2a CHC combined with T2DM admitted to Zhangye People's Hospital Affiliated to Hexi College from January 2020 to December 2022 were conveniently selected for the study,and were divided into the control group and the observation group,each with 81 cases,by random number table method.The control group was given ribavirin+interferon treatment,and the observation group was added sofosbuvir and velpatasvir treatment on the basis of the control group.Compare the clinical efficacy,viral response rate,liver function indexes,inflammatory factors,and treatment safety of the two groups.Results The total effective rate of treatment the observation group was 92.59%,which was higher than that of the control group of 79.01%,and the difference was statistically significant(χ^(2)=6.131,P<0.05).The early virological response rate,virological response rate at the end of treatment,viral response rate 24 weeks after drug cessation and viral response rate 48 weeks after drug cessation of patients in the observation group were higher than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the liver function indexes of the observation group were lower than those of the control group,and the differences were statistically significant (all P<0.05). After treatment, the levels of inflammatory factors in the observation group were all lower than those in the control group, and the differences were statistically significant (all P<0.05). Comparing the occur rence of adverse reactions in the two groups, the difference was not statistically significant (P>0.05). Conclusion Sofos buvir and velpatasvir is effective in the treatment of patients with genotype 2a CHC combined with T2DM, which can improve the viral response rate of the patients, improve the liver function inde

关 键 词：慢性丙型肝炎 2型糖尿病 索磷布韦维帕他韦 肝功能 病毒应答率 炎症因子 

分 类 号：R5[医药卫生—内科学]